Median follow-up was 12.71 months (7 - 20 months) including 61 (28.2%) PTMC patients with excellent response (ER), 47 (21.6%) patients with biochemical incomplete response (BCIR), 35 (16.5%) patients with structural incomplete response (SIR) and 73 (33.8%) patients with indeterminate response (IR).